Bio-Techne Statistics
Total Valuation
Bio-Techne has a market cap or net worth of $9.07 billion. The enterprise value is $9.15 billion.
| Market Cap | 9.07B |
| Enterprise Value | 9.15B |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | May 18, 2026 |
Share Statistics
Bio-Techne has 156.57 million shares outstanding. The number of shares has decreased by -2.32% in one year.
| Current Share Class | 156.57M |
| Shares Outstanding | 156.57M |
| Shares Change (YoY) | -2.32% |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 117.01% |
| Float | 155.96M |
Valuation Ratios
The trailing PE ratio is 83.40 and the forward PE ratio is 28.86. Bio-Techne's PEG ratio is 4.05.
| PE Ratio | 83.40 |
| Forward PE | 28.86 |
| PS Ratio | 7.49 |
| Forward PS | 7.27 |
| PB Ratio | 4.35 |
| P/TBV Ratio | 11.51 |
| P/FCF Ratio | 33.65 |
| P/OCF Ratio | 30.77 |
| PEG Ratio | 4.05 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 24.99, with an EV/FCF ratio of 33.93.
| EV / Earnings | 83.54 |
| EV / Sales | 7.56 |
| EV / EBITDA | 24.99 |
| EV / EBIT | 29.54 |
| EV / FCF | 33.93 |
Financial Position
The company has a current ratio of 4.49, with a Debt / Equity ratio of 0.14.
| Current Ratio | 4.49 |
| Quick Ratio | 2.80 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 1.08 |
| Interest Coverage | 31.98 |
Financial Efficiency
Return on equity (ROE) is 5.34% and return on invested capital (ROIC) is 10.62%.
| Return on Equity (ROE) | 5.34% |
| Return on Assets (ROA) | 7.45% |
| Return on Invested Capital (ROIC) | 10.62% |
| Return on Capital Employed (ROCE) | 12.92% |
| Weighted Average Cost of Capital (WACC) | 11.43% |
| Revenue Per Employee | $390,584 |
| Profits Per Employee | $35,322 |
| Employee Count | 3,100 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 2.07 |
Taxes
In the past 12 months, Bio-Techne has paid $37.58 million in taxes.
| Income Tax | 37.58M |
| Effective Tax Rate | 25.54% |
Stock Price Statistics
The stock price has increased by +17.05% in the last 52 weeks. The beta is 1.36, so Bio-Techne's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | +17.05% |
| 50-Day Moving Average | 52.49 |
| 200-Day Moving Average | 57.49 |
| Relative Strength Index (RSI) | 64.79 |
| Average Volume (20 Days) | 2,802,816 |
Short Selling Information
The latest short interest is 13.85 million, so 8.84% of the outstanding shares have been sold short.
| Short Interest | 13.85M |
| Short Previous Month | 14.55M |
| Short % of Shares Out | 8.84% |
| Short % of Float | 8.88% |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Bio-Techne had revenue of $1.21 billion and earned $109.50 million in profits. Earnings per share was $0.69.
| Revenue | 1.21B |
| Gross Profit | 803.97M |
| Operating Income | 309.72M |
| Pretax Income | 147.14M |
| Net Income | 109.50M |
| EBITDA | 366.05M |
| EBIT | 309.72M |
| Earnings Per Share (EPS) | $0.69 |
Balance Sheet
The company has $214.11 million in cash and $290.32 million in debt, with a net cash position of -$76.21 million or -$0.49 per share.
| Cash & Cash Equivalents | 214.11M |
| Total Debt | 290.32M |
| Net Cash | -76.21M |
| Net Cash Per Share | -$0.49 |
| Equity (Book Value) | 2.09B |
| Book Value Per Share | 13.32 |
| Working Capital | 534.77M |
Cash Flow
In the last 12 months, operating cash flow was $294.86 million and capital expenditures -$25.26 million, giving a free cash flow of $269.60 million.
| Operating Cash Flow | 294.86M |
| Capital Expenditures | -25.26M |
| Depreciation & Amortization | 56.33M |
| Net Borrowing | -130.00M |
| Free Cash Flow | 269.60M |
| FCF Per Share | $1.72 |
Margins
Gross margin is 66.40%, with operating and profit margins of 25.58% and 9.05%.
| Gross Margin | 66.40% |
| Operating Margin | 25.58% |
| Pretax Margin | 12.15% |
| Profit Margin | 9.05% |
| EBITDA Margin | 30.23% |
| EBIT Margin | 25.58% |
| FCF Margin | 22.27% |
Dividends & Yields
This stock pays an annual dividend of $0.32, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | $0.32 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.06% |
| Buyback Yield | 2.32% |
| Shareholder Yield | 2.87% |
| Earnings Yield | 1.21% |
| FCF Yield | 2.97% |
Analyst Forecast
The average price target for Bio-Techne is $61.69, which is 6.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $61.69 |
| Price Target Difference | 6.47% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | 4.29% |
| EPS Growth Forecast (3Y) | 6.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 30, 2022. It was a forward split with a ratio of 4:1.
| Last Split Date | Nov 30, 2022 |
| Split Type | Forward |
| Split Ratio | 4:1 |
Scores
Bio-Techne has an Altman Z-Score of 13.08 and a Piotroski F-Score of 7.
| Altman Z-Score | 13.08 |
| Piotroski F-Score | 7 |